Role of 2D-shear Wave Spleen Elastography in Assessing Clinically Significant Portal Hypertension and High-risk Varices in Advanced Chronic Liver Disease

What this Trial Is About

Researchers are evaluating the use of spleen shear wave elastography (SWE-SSM) to diagnose clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD) and to identify high-risk esophageal varices (HRV) in those with CSPH. The study also aims to examine how SWE-SSM correlates with portal pressure in certain patients undergoing hepatic venous pressure gradient (HVPG) measurements and with transient elastography (TE-SSM). During routine ultrasound examinations required by the patient's care plan, values of SWE-SSM and liver shear wave elastography (SWE-LSM) will be measured. If patients meet the inclusion criteria and provide informed consent, an additional spleen elastography will be performed as a non-invasive diagnostic test without changing the standard ultrasound procedure or affecting the patient's treatment or disease progression. Participants will undergo ultrasound assessments where spleen and liver elastography data are collected. The study will not introduce any treatment or intervention that alters the patient's condition. Researchers will monitor and analyze these measurements to better understand CSPH and high-risk varices over a 2-year period, focusing on the primary outcome related to CSPH.

2D-shear Wave Spleen Elastography in Clinically Significant Portal Hypertension and High-risk Varices